FUTURE OF HEALTHCARE

SpineGuard Announces a New Partnership with Sorbonne, CNRS and Inserm to associate its DSG® Technology With Ultrasound and Serve Surgical Robots

SpineGuard | June 08, 2022

SpineGuard Announces

pineGuard an innovative company that deploys its DSG sensing technology to secure and streamline the placement of bone implants, announces the launch of a new three-year collaboration program with two labs of Sorbonne University CNRS and Inserm: the ISIR.

DSG is based on the local measurement of electrical conductivity of tissues in real time without X-ray imaging, with a sensor located at the tip of the drilling instrument. Its efficacy was proven by more than 90,000 surgeries across the globe and 19 scientific publications. SpineGuard has entered in 2017 a collaboration with ISIR for the application of DSG to surgical robots and the enhancement of their safety, accuracy, and autonomy.

SpineGuard and ISIR capitalize on first order outcomes published so far…

At the close of a first collaboration phase, SpineGuard announced sub-millimetric accuracy experimental outcomes in bone boundary detection and automatic stop of a vertebral drilling performed by a robot using the DSG technology. These impressive outcomes were presented as they were produced successively at the Hamlyn medical robotics conference in London in May 2019, receiving the first price for best scientific paper, then in plenary session at the SMISS minimally invasive spine surgery (SMISS) in Las Vegas in November 2021, and lastly during the CRAS conference in Naples in April 2022.

… and join forces with the LIB laboratory in order to add ultrasound to the project.

Encouraged by this success, the research and development teams wish to go even further in surgical robots advancement: the guidance technologies that allow the robot to position itself properly relative to the patient to find the drilling entry point rely today on X-Ray imaging, dangerous for health, in combination with space-consuming optical registration. SpineGuard has long explored the possibility to use ultrasound complementarily to DSG for this preliminary step, before the tool is penetrating bone, and was granted two families of international patents on that topic. The LIB laboratory, who features an international level expertise in the field of ultrasound imaging, answered with enthusiasm the invitation to join the project. SpineGuard, ISIR and LIB thus start a new 3-year collaboration that is expected to produce breakthrough results in the field.

We are happy to launch this partnership that will allow us to go even further in improving surgical robots in orthopedics. This new phase of the project aims at enabling robots to perform bone drilling and cutting, as well as implant placement, in a secured and more autonomous manner in the human skeleton. Our goal is to implement first-class collaboration between French Research and Industry and trigger commercial ventures in the orthopedic field via strategic agreements with industry partners.”

Stéphane Bette, co-founder and Deputy CEO of SpineGuard

Guillaume Morel, Professor at Sorbonne University and ISIR Director, and Brahim Tamadazte, Researcher at CNRS and member of ISIR, added: “We are delighted to continue the close and dynamic collaboration initiated in 2017 with SpineGuard. The entry of robotics and associated new technologies in operating room is no doubt one of the biggest medical advances of the last twenty years. Robotic approaches often allow the surgical gesture to be less invasive, more accurate, safe and intuitive in numerous surgical procedures. The first outcomes from the previous collaboration gave us more visibility on the clinical added value that a robot with original and effective sensors can bring to Orthopedic Surgery in general and Spine in particular. This new collaboration will be about ultrasonic sensors coupled with robotics. This original and promising association will allow the surgeon to define the entry point and the pedicle screw trajectory accurately and non-invasively, without relying on ionizing or costly preoperative imaging (scanner, MRI). The association of two prestigious labs of Sorbonne University (ISIR and LIB), whose competencies are highly complementary to SpineGuard’s industrial vision constitute a stimulating work environment favorable to innovation. The journey with SpineGuard goes on for three more years with a target of several technologic and scientific innovations to serve patients and care providers.”

Quentin Grimal, Professor at Sorbonne University and Manager of the team “Ultrasound and imaging for bone quality characterization” at LIB, concludes: “Using ultrasound to position a surgical tool is particularly relevant. Ultrasounds are danger free and provide real time information about interfaces, bone anatomy, even bone mechanical quality. The use of an ultrasound probe should allow to position the robotic arm in an optimal manner to place pedicle screws. In general, echography does not allow to see beyond the bone surfaces because ultrasounds are strongly reflected at the surface and strongly attenuated when propagating in bone. Low amplitude signals coming from inside bone can however be exploited through specific treatments which are a specialty of our team. Our team, pioneer in ultrasound utilization to probe bone, has introduced several approaches that offer an alternative to X-Rays for characterization of trabecular or cortical bone health. For our team, this partnership with SpineGuard and ISIR is a great fit: it will accelerate methodology and instrument developments for a broader utilization of ultrasound in orthopedic surgery. We are very happy to participate in this innovation rich project.”

About SpineGuard®

Founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard is an innovative company deploying its proprietary radiation-free real time sensing technology DSG® (Dynamic Surgical Guidance) to secure and streamline the placement of implants in the skeleton. SpineGuard designs, develops and markets medical devices that have been used in over 90,000 surgical procedures worldwide. Nineteen studies published in peer-reviewed scientific journals have demonstrated the multiple benefits DSG® offers to patients, surgeons, surgical staff and hospitals. Building on these strong fundamentals and several strategic partnerships, SpineGuard has expanded the scope of its DSG® technology in innovative applications such as the « smart » pedicle screw, the DSG Connect visualization and registration interface, dental implantology and surgical robotics. DSG® was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. SpineGuard has engaged in multiple ESG initiatives.

About ISIR

ISIR is one of the largest French Research institutions in robotics and intelligent systems, reporting mainly to Sorbonne University, CNRS (National Center for Scientific Research) and Inserm (National institute for health and medical research). It regroups more than 50 teaching researchers and permanent researchers and approximately 80 PhD ad post-doc students. ISIR is structured around 6 research teams focused on artificial intelligence and machine learning, mobile robotics, small scale robotics, assistance robotics (physical therapy and mobility support), human-robot interaction and surgical gesture assistance. ISIR has a rich expertise in the design of innovative robotic architectures, simulation and control, clinical validation and transfer of high industrial potential results. Over the last 5 past years, 10 pre-clinical or clinical studies were conducted at ISIR. 8 patents were granted, and 2 start-up companies created.

About LIB

The Laboratory for biomedical imaging (LIB) is specialized in Fundamental and Applied Research for biomedical morphologic imaging methods, functional and molecular on small animal and human. It reports to Sorbonne University, CNRS and INSERM. It regroups 35 permanent researchers and teaching researchers, of whom half are also hospital practitioners, approximately 10 engineers and technicians and more than 30 PhD students and post-docs. LIB is structured around 6 teams whose focuses correspond to key priorities of 21st century Public Health: cancer, cardiovascular and neurologic diseases, bone quality. LIB develops new diagnostic and treatments methods exploiting various modalities: ultrasound, MRI, CT, SPECT-PET, etc. LIB has a strong commitment to technology transfer. Over the last 5 years, 6 patents were granted, 7 software were filed, and 5 startup companies launched.

Spotlight

The Integrity Home Health & Hospice team consists of professionals that have dedicated their careers to home health and hospice care. Since we are unrelentingly dedicated to providing quality care, we seek out the very best geriatric professionals to care for our patients. Integrity Home Health & Hospice was founded as an employee-owned company to ensure that our employees are invested in our success and reputation.

Spotlight

The Integrity Home Health & Hospice team consists of professionals that have dedicated their careers to home health and hospice care. Since we are unrelentingly dedicated to providing quality care, we seek out the very best geriatric professionals to care for our patients. Integrity Home Health & Hospice was founded as an employee-owned company to ensure that our employees are invested in our success and reputation.

Related News

HEALTHTECH SECURITY

KORU Medical Systems Appoints Brent Rutland as Vice President of Medical Affairs

KORU Medical | October 13, 2022

KORU Medical Systems, Inc. a leading medical technology company focused on the development of innovative and easy-to-use subcutaneous infusion solutions announced the appointment of Brent Rutland as the Company’s new Vice President of Medical Affairs. Mr. Rutland will provide leadership in the Company’s clinical and data generation strategies, key opinion leader engagement, assessing new subcutaneous drug candidates for use with the Company’s products and overseeing the medical affairs team. Additionally, Mr. Rutland will be the clinical resource for the Company’s efforts in regulatory submissions, failure modes and effects analysis, health hazard evaluations, human factors design, new product development and clinical evaluation updates. “We are excited to bring Brent’s competence to the organization – his background was a perfect fit. His expertise will advance clinical evidence generation in support of our product pipeline, provide valuable insight to our drug therapy candidates and help develop important key opinion leader relationships. Brent has helped build multiple data and clinical strategies, internal teams, and external networks in his past. His deep industry experience and passion for the patient, will make him an impactful contributor to the Company’s strategy.” Linda Tharby, President and CEO Mr. Rutland’s career history spans an impressive 27 years and includes working with Baxter Healthcare as a Senior Medical Science Liaison and most recently with La Jolla Pharmaceutical Company as a Senior Director, Health Outcomes. During his career he helped launch 7 vaccines, 4 drugs and 1 device. Most notably, Brent aided Baxter in the launch of Hylenex for SQ rehydration where he also helped build the Medical Affairs department. He has received several awards throughout his career, with the most recent being the President’s Circle Award for Medical Affairs at La Jolla. Brent holds a Bachelor of Science degree from Texas A&M University, an MBA in Global Management from the University of Houston, and his Master of Public Health from the University of North Carolina in Epidemiology. “I was immediately drawn to the opportunity to work at KORU Medical as I saw the potential for future growth supported by building out the medical science and the team,” said Brent Rutland, Vice President of Medical Affairs. “Medical affairs helps fulfill the unmet needs of the patient through the generation and delivery of scientific evidence to various key outside stakeholders. I look forward to developing a collaborative strategy to support the Company’s overall goals.” About KORU Medical KORU Medical develops, manufactures, and commercializes innovative and easy-to-use subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System. currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.

Read More

HEALTH TECHNOLOGY

IQVIA Decentralized Clinical Trial Program Achieves Independent GDPR Validation

IQVIA | September 29, 2022

IQVIA a leading global provider of advanced analytics, technology solutions and contract services to the life sciences industry announced its Decentralized Clinical Trial (DCT) program has received GDPR compliance validation from TRUSTArc. This marks the first instance of a DCT service receiving this European data privacy validation. TRUSTArc’s third-party validation demonstrates that IQVIA’s DCT program processes personal data in accordance with GDPR, allowing customers to address participant and investigator privacy concerns that may arise because of their participation in decentralized trials. “At IQVIA, we are committed to delivering decentralized studies, we recognize the criticality of patient data protection in doing this and we understand the focus on data protection by European regulators,” said Ronan Brown, SVP and head of Patient Centric Solutions & Decentralized Trials. “IQVIA is proud to have this validation prove our longstanding dedication to data protection in decentralized trials.” TRUSTArc maps it’s GDPR Validation requirements to applicable GDPR Articles and ISO 27001 standards, alongside the standards of it’s own Privacy and Data Governance Accountability Framework. This validation is yet another step IQVIA has taken to enable DCTs to be brought to a wider group of participants, improving diversity, sustainability, and trust in clinical development. “Achieving a GDPR validation demonstrates IQVIA’s commitment to ensuring the highest standards of delivering decentralized studies to the people it serves. Organizations of all sizes must become privacy-forward to earn the trust of their customers. IQVIA has consistently prioritized being privacy-forward to earn the trust of their customers and the TRUSTArc GDPR and CCPA Validations reinforce that standing.” Chris Babel, CEO, TRUSTArc About IQVIA IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 82,000 employees, IQVIA conducts operations in more than 100 countries. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures.

Read More

FUTURE OF HEALTHCARE

Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment

Brain Navi Biotechnology Co., Ltd. | September 12, 2022

Brain Navi, the leading surgical robot manufacture in Taiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region, Jordan, Egypt plus other countries in the Middle East and Philippines, Indonesia, Malaysia, and Singapore which will be covered by Medtreq branch in Philippines. NaoTrac, a CE-certified and local government approval neurosurgical navigation robot from Brain Navi Biotechnology, is embedding dissimilar technology named SMART Technology which combining the machine vision and in-house algorithm to perform robot-assisted surgery, to streamline surgical procedures with real-time imaging and minimal invasive outcomes. "We are always scouting for the new technology to help as many people as we can. We have many neurosurgeons coming from Riyadh and some other territories keening and willing to learn more about this technology, and the NaoTrac from Brain Navi is one of them. We are always happy to partner with an innovative technology company," Sherif Bayoumy, the General Manager of Medtreq Medical Equipment The collaboration and partnership between Brain Navi and Medtreq enables greater innovative outcome in the Middle East neurosurgery, such as Saudi Arabia, UAE, Egypt, Jordan, and some of the other countries on progressing, to streamline the surgical procedure, improve the surgical accuracy and pass-on knowledge to shorten the learning curves. "We seek strategic partners that can accelerate Brain Navi's growth mission. This partnership is a significant step toward scaling our business and getting more robot-assisted neurosurgery into the world," said Jerry Chen, the CEO of Brian Navi Biotechnology. "The collaboration between Metreq and Brain Navi is looking positive because we share the same mission to innovate with technology to make the life bright. We truly believe that the collaboration between Brain Navi and Medtreq can maximum the value of both sides to bring the neurosurgery to the next level." About Metreq Medical Equipment Bahrain Medtreq Medical Equipment provides professional technical support and after-service to clients in the MENA region with a presence in Bahrain and GCC, Egypt, North Africa, Turkey, Europe, the United States (Medtreq Tenessee USA), and the Philippines, Singapore, Malaysia, and Indonesia. Medtreq is built on high values, principles, and social commitment to society and humanity. About Brain Navi Brain Navi Biotechnology is a leading Taiwanese surgical robotic company. We design and develop innovative navigation and robotic surgery technologies for surgeons to improve surgical accuracy. Brain Navi's exclusive Surface Mapping Auto-registration Technology (SMART) is a significant surgical robotic breakthrough that merges machine vision, robotics, and AI technology to achieve streamlined surgical procedures with real-time imaging and minimal invasive outcomes.

Read More